Central nervous system leukemia
disease diseaseOn this page
Also known as central nervous system leukaemia (disease)central nervous system leukemia (disease)CNS leukaemiaCNS leukemialeukaemia (disease) of central nervous systemleukaemia of central nervous systemleukaemia of CNSleukaemia of the central nervous systemleukaemia of the CNSleukemia (disease) of central nervous systemleukemia of central nervous systemleukemia of CNSleukemia of the central nervous systemleukemia of the CNS
Summary
Central nervous system leukemia (MONDO:0001606) is a cancer and 4 clinical trials. Top therapeutic interventions include mercaptopurine anhydrous, dasatinib anhydrous, and daunorubicin hydrochloride. A subtype of central nervous system hematopoietic neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 4
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | central nervous system leukemia |
| Mondo ID | MONDO:0001606 |
| DOID | DOID:12969 |
| NCIT | C5440 |
| UMLS | C1332884 |
| MedGen | 234102 |
| GARD | 0022972 |
| Anatomy (UBERON) | UBERON:0001017 |
| Is cancer (heuristic) | yes |
Also known as: central nervous system leukaemia (disease) · central nervous system leukemia · central nervous system leukemia (disease) · CNS leukaemia · CNS leukemia · leukaemia (disease) of central nervous system · leukaemia of central nervous system · leukaemia of CNS · leukaemia of the central nervous system · leukaemia of the CNS · leukemia (disease) of central nervous system · leukemia of central nervous system · leukemia of CNS · leukemia of the central nervous system · leukemia of the CNS
Disease family
This is a subtype of central nervous system hematopoietic neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › central nervous system neoplasm › central nervous system hematopoietic neoplasm › central nervous system leukemia
Related subtypes (3): intracranial cavernous angioma, primary central nervous system lymphoma, pituitary gland basophil adenoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 4.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
| PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03959085 | PHASE3 | RECRUITING | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy |
| NCT02883049 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations |
| NCT05735717 | PHASE2 | RECRUITING | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies |
| NCT05667402 | Not specified | UNKNOWN | Clinical Study of TBF Regimen in Allo-HSCT in Patients With CNS Leukemia |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| MERCAPTOPURINE ANHYDROUS | 4 | 6 |
| DASATINIB ANHYDROUS | 4 | 2 |
| DAUNORUBICIN HYDROCHLORIDE | 4 | 2 |
| PEGASPARGASE | 4 | 2 |
| THIOGUANINE | 4 | 2 |
| BLINATUMOMAB | 4 | 1 |
| CALASPARGASE PEGOL | 4 | 1 |
| CLOFARABINE | 4 | 1 |
| HYDROCORTISONE SODIUM SUCCINATE | 4 | 1 |
| INOTUZUMAB OZOGAMICIN | 4 | 1 |
| CHEMBL4583196 | 0 | 1 |